New drug HBM7020 tested in humans for first time against autoimmune diseases
NCT ID NCT07649265
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This first-in-human study tests the safety of a new drug called HBM7020. It will first be given to healthy volunteers at low doses, then to people with moderate to severe autoimmune diseases like lupus, rheumatoid arthritis, scleroderma, and Sjögren's disease. The goal is to see if the drug is safe and how the body processes it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HBM7020
- What this could lead to
- If safe, this could lead to a new treatment option for autoimmune diseases like lupus and rheumatoid arthritis.
- What could go wrong
- This is a very early Phase 1 trial with only 63 people, so safety and effectiveness are not yet known. Side effects like immune reactions are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can group learning make biotherapy safer for arthritis patients?
- Can a new biologic tame lupus flares?